Drug Discovery - Research & Development

Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML

Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, has announced a $42m Series A financing round led by 5AM Ventures and RA Capital Management.

AbbVie, Teneobio sign deal to develop new treatment for multiple myeloma

AbbVie, Teneobio, and its affiliate TeneoOne have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Samsung Bioepis, C-Bridge Capital to develop and commercialize next-generation biosimilars in China

Samsung Bioepis has announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.

Evotec, Galapagos enter into collaboration in fibrosis field

Evotec and Galapagos have announced a global collaboration focused on a novel target for fibrosis and other indications.

Ligand announces OmniAb partnership with Genagon Therapeutics

Ligand Pharmaceuticals has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.

TamRx launches to develop pipeline of immuno-oncology products for treatment of cancers

BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, announced the formation of a new biotech start-up, TamRx.

Frazier Healthcare Partners launches Recida Therapeutics to develop therapeutics for serious antibiotic-resistant infections

Frazier Healthcare Partners has launched Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections.

GSK, Merck enter into €3.7bn deal for novel cancer treatment

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal.

Amprologix wins DHSC backing for new antibiotic

Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.